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Abstract
Background: Intestinal fatty-acid binding protein (I-FABP) is expressed in epithelial cells of the mucosal layer of the
small intestine tissue. When intestinal mucosal damage occurs, I-FABP is released into the circulation and its plasma
concentration increases. In the context of obesity, the gut barrier integrity can be disrupted by dietary fat while
intestinal permeability increases.
Objective: To investigate whether intestinal fatty acid binding protein (I-FABP) is a suitable plasma marker of
intestinal injury and inflammation in obesity.
Methods: Twelve male Wistar rats were randomly divided into two groups of six animals each: standard (St) and
high-fat (HF) diet fed groups for 12 weeks.
Results: HF fed animals developed obesity, insulin resistance and seemed to present increased plasma levels of
proinflammatory cytokines (MCP-1 and IL1β). The gut microbiota composition of these animals was also altered,
with lower number of copies of Bacteroidetes, Prevotella spp. and Lactobacillus spp., in comparison with those
from St diet group. Fecal lipopolysaccharide (LPS) concentrations tended to be increased in HF fed animals.
Intestinal expression of TLR4 seemed to be also increased in HF fed animals suggesting that HF diet-induced
dysbiosis may be behind the systemic inflammation observed. However, in contrast to other intestinal inflammatory
diseases, plasma I-FABP levels were decreased in HF fed rats whereas I-FABP expression in jejunum tended to be
increased.
Conclusions: HF diet-induced obesity is characterized by dysbiosis, insulin resistance and systemic inflammation. In
this context, plasmatic I-FABP should not be used as a marker of the intestinal barrier dysfunction and the low-
grade chronic inflammatory status.
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Background
The new concepts on the pathophysiology of obesity and
insulin resistance highlight the role of intestinal micro-
biota and intestinal barrier in the development of these
disorders [1, 2]. Microbiota seems to mediate obesity and
associated metabolic disturbances through several
mechanisms including energy storage and metabolic
inflammation [1, 3]. On the other hand, intestinal mucosa
plays not only an important part in the absorption of vital
nutrients, but also in anatomical/barrier and immune
functions, preventing bacterial translocation. High-fat diet
changes gut microbiota composition and increases intes-
tinal permeability, by a mechanism associated with a
reduced expression of epithelial tight junction proteins
[4]. The altered intestinal barrier and the subsequent
translocation of bacteria or bacterial products, namely
lipopolysaccharide (LPS) are now recognized as key
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mediators of the low-grade inflammation state, which
characterize metabolic disorders.
Intestinal fatty-acid binding protein (I-FABP) is an intra-
cellular protein specifically and abundantly expressed in
the epithelial cells of the mucosal layer of the small and
large intestine tissue [5]. The location of I-FABP in the
mature epithelium of villi facilitates its leakage into the
circulation from enterocytes when intestinal mucosal
damage occurs [5]. It has been shown that I-FABP is re-
leased into the circulation following small intestinal mu-
cosal injury and its plasma concentration has been
associated with small intestinal diseases - necrotizing en-
terocolitis and celiac disease [6–8]. Therefore, I-FABP has
emerged as a possible non-invasive marker for evaluating
gut wall integrity loss and inflammation. Defining new
and early non-invasive markers of gut barrier dysfunction
might be of great interest in order to manage a safe modu-
lation of the intestinal microbiota before emergence of
obesity and associated metabolic diseases.
The aim of this study was to investigate the role of I-
FABP as a possible plasma marker of intestinal injury
and inflammation and its relationship with microbiota
dysbiosis in a high-fat diet-induced obesity Rat model.
Methods
Animals and housing
Twelve male Wistar rats were purchased from Charles
River (Barcelona, Spain) and kept under controlled en-
vironmental conditions (22–24 °C and 12 h light/dark
cycles), for at least 1 week before starting the experi-
ments. Animals, 8 weeks of age, were randomly divided
into two groups of six animals each: standard (St) and
high-fat (HF) diet group. The diets were respectively “St”
(Teklad 2014, Harlan Laboratories, Santiga, Spain) and
“HF” with 45 % of energy from lipids and 17 % of energy
from sucrose (D12451 Research Diets, New Brunswick,
NJ, USA). Animals were subjected to different experi-
mental conditions for a total of 12 weeks. The water and
chow were supplied ad libitum. Food and beverage con-
sumption and body weight were monitored weekly, to
carefully characterize energy ingestion and weight gain.
At the end of the 12 weeks, food was removed 4–6 h be-
fore sacrifice and the animals were anesthetized with a
mixture of ketamine (50 mg/kg) and medetomidine
(1 mg/kg) and maintained with isoflurane. Meanwhile,
using a Quantum/S bioelectrical impedance analyzer (RJL
Systems, Akern SRL, Florence, Italy), the body compos-
ition of each rat was determined by bioelectrical imped-
ance, according to the procedure already described in the
literature [9]. Before perfusion of the vascular compart-
ment with a saline solution (NaCl 0.9 %, w/v), blood
was drawn from the left ventricle into tubes with or
without heparin to obtain plasma and serum, respect-
ively. Aliquots were frozen at −80 °C until further
analysis. Colon and jejunum were dissected, pat dried
and snap-frozen in liquid nitrogen. Fresh fecal sam-
ples were collected directly from the colon of all
animals and snap-frozen in liquid nitrogen. Both tis-
sues and fecal samples were stored at −80 °C until
further analysis.
Animal handling and housing protocols followed
European Union guidelines (Directive 2010/63/EU) for
the use of experimental animals in scientific research.
The protocol was approved by the Committee on the
Ethics of Animal Experiments of the Faculty of Medicine
of University of Porto.
Oral glucose tolerance test (OGTT)
After 7 weeks of treatment, rats were fasted over 5 h and
a baseline blood draw from the saphenous vein was col-
lected for plasma fasting glucose and insulin measure-
ments. Animals were gavaged with a glucose solution of
2 g/kg body weight and blood droplets from the saphe-
nous vein were collected to measure glycaemia thereafter
at 30, 60, 90 and 120 min. Glucose levels were measured
with Precision Xtra Plus test strips and an Optium Xceed
device (Abbott Diabetes Care, Ltd., Maidenhead, UK).
Plasma insulin levels were measured using a Rat/Mouse
Insulin ELISA kit (Merck Milipore, Madrid, Spain). The
homeostasis model assessment (HOMA) was used to
calculate approximate insulin resistance using the formula:
glucose (mg/dL) × insulin (ng/mL)/405.
Blood and biochemical analysis
Biochemical evaluation of plasma was performed at the
end of the study at São João Hospital Center Clinical
Pathology Department. Routine biochemical parameters
were measured using conventional methods with an
Olympus AU5400® automated clinical chemistry analyzer
(Beckman-Coulter, Izasa, Porto, Portugal).
Plasma content in leptin, adiponectin, monocyte chemo-
attractant protein-1 (MCP-1), I-FABP and glucagon-like
peptide-2 (GLP-2) were determined using, respectively,
Rat Leptin ELISA Kit (Merck, Milipore, Madrid, Spain),
Human/Mouse/Rat Adiponectin Enzyme Immunoassay
Kit (RayBiotech, Norcross, GA, USA), Rat MCP-1 ELISA
Kit (RayBiotech, Norcross, GA, USA), Rat (FABP2) ELISA
Kit (Shanghai Sunred Biological Technology Co., Ltd,
Shangai) and GLP-2 ELISA Kit (Merck, Milipore, Madrid,
Spain). Serum interleukin-1 beta (IL-1β) was determined
by Luminex assay using custom Miliplex Rat Kits (Merck
Milipore, Madrid, Spain), according to the manufacturer’s
protocols using the Luminex Xmap Multiplexing Tech-
nology platform.
Tissue RNA isolation and qRT-PCR
Total RNA from jejunum and colon was isolated using
NZYol reagent (NZYTech, Portugal) according to
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manufacturer’s instructions. RNA samples were treated
with DNase I (RQ1 RNase-free DNase; Promega,
Portugal). cDNA was synthesized from 1 μg of treated
mRNA with NZY First-Strand cDNA Synthesis Kit
(NZYTech, Portugal). Quantitative real-time polymerase
chain reaction (qRT-PCR) was run on Lightcycler96
(Roche Applied Science, Indianapolis, ID, USA). Cycling
conditions were as follows: denaturation (95 °C for
10 min), amplification and quantification (95 °C for 10 s,
annealing temperature for 10 s and 72 °C for 10 s, with
a single fluorescence measurement at the end of the 72 °
C for a 10-s segment) repeated for 45 cycles and a final
melting step with a temperature ramp from 60 to 97 °C.
Rat-specific primer sequences (Sigma-Aldrich, St. Louis,
MO, USA) used are described in Table 1. The Cq values
obtained were transformed into relative quantification
data using the formula 2−(ΔCq).
DNA extraction from stool
Genomic DNA was extracted and purified from stool
samples using NZY Tissue gDNA Isolation Kit (NZY-
tech, Lisbon, Portugal) with some modifications. Briefly,
feces (170–200 mg) were homogenized in TE buffer
(10 mM Tris/HCl; 1 mM EDTA, pH 8.0) and centri-
fuged at 4000 x g for 15 min. The supernatant was
discarded and the pellet was resuspended in 350 μL of
buffer NT1. After an incubation step at 95 °C for
10 min, samples were centrifuged at 11000 x g for
1 min. Then, 25 μL of proteinase K were added to
200 μL of the supernatant for incubation at 70 °C for
10 min. The remaining steps followed manufacturer’s in-
structions. DNA purity and quantification were assessed
with a NanoDrop spectrophotometer (Thermo Scientific,
Wilmington, DE, USA).
Microbial analysis of Rat stool by qRT-PCR
qRT-PCR was performed in sealed 96-well microplates
using a LightCycler FastStart DNA Master SYBR Green
kit and a LightCycler96 instrument (Roche Applied Sci-
ence, Indianapolis, ID, USA). Primer sequences (Sigma-
Aldrich, St. Louis, MO, USA) used to target the 16S
rRNA gene of the bacteria and the conditions for PCR
amplification reactions were previously described in
Marques C et al. [10]. To verify the specificity of the
amplicon, a melting curve analysis was performed via
monitoring SYBR Green fluorescence in the temperature
ramp from 60 to 97 °C. Data were processed and ana-
lyzed using the LightCycler software (Roche Applied Sci-
ence, Indianapolis, ID, USA). Standard curves were
constructed using serial tenfold dilutions of bacterial
genomic DNA, according to the following webpage
http://cels.uri.edu/gsc/cndna.html. Bacterial genomic
DNA used as a standard was obtained from DSMZ
(Braunschweig, Germany). Genome size and the copy
number of the 16S rRNA gene for each bacterial strain
used as a standard was obtained from NCBI Genome
database (www.ncbi.nlm.nih.gov). Data are presented as
the mean values of duplicate PCR analysis.
Fecal LPS quantification
Quantification of LPS was performed using the Chromo-
Limulus Amebocyte Lysate (Chromo-LAL) reagent (Asso-
ciates of Cape Cod, Inc., Falmouth, MA, USA). Briefly,
1 mL of sterile saline solution (NaCl 0.9 %) was added to
100 mg feces, vortexed and centrifuged (10 min, 10000 g,
4 °C) twice. Total supernatant (fecal water) was filtered
with 0.45 μm filter and then with 0.22 μm filter. Fecal
water and Chromo-LAL (1:1) were incubated at 37 °C for
20 min and absorbance was read every 10 s at 405 nm.
Statistical analysis
Values are expressed as the arithmetic mean ± standard
error of the mean (SEM). Given the small sample size, a
non-parametric test (Mann–Whitney test) was used to
analyze the differences between St and HF groups.
Correlation between variables was established using two-
tailed Pearson’s correlation test. The differences were
considered statistically significant when P <0.05. All stat-
istical analyses were performed using GraphPad Prism 6
statistical software (GraphPad Software Inc., La Jolla,
CA, USA).
Results
Energy and metabolic parameters
Energy intake was increased in the HF diet fed group
when compared with St diet fed group (72.60 ± 0.15 vs.
57.9 ± 0.47 kcal/day, P <0.05). Consequently, HF diet fed
animals gained more weight during the 12 weeks of the
study (205.5 ± 37.8 vs. 134.7 ± 22.5 g, P <0.05) (Table 2).
To assess whether these differences in weight gain were
related to alterations in adiposity, we decided to evaluate
the body composition of the animals of both groups.
Our results showed that rats under HF diet had more
body fat mass comparing to rats under St diet (206.3 ±
21.03 vs. 166.8 ± 21.26, P <0.05).
Table 1 Primer sequences and real-time PCR conditions used
for gene expression analysis by qRT-PCR
Gene name Primer Sequence (5’-3’) AT
I-FABP ATGGAAAGGAGCTGATTGCT 59 °C
TTGGCCTCCACTCCTTCATA
TLR4 GATGCCTCTCTTGCATCTGG 60 °C
TCATGAGGGATTTTGCTGAGA
GAPDH GGCATCGTGGAAGGGCTCATGAC 62 °C
ATGCCAGTGAGCTTCCCGTTCAGC
AT annealing temperature, GAPDH glyceraldehyde-3-phosphate dehydrogenase
(housekeeping gene), I-FABP intestinal fatty acid binding protein, TLR4 Toll-like
receptor 4
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To assess glycemic response, we performed an oral
glucose tolerance test (OGTT). The total area under the
curve (AUC) of the glycemic response was increased by
HF diet feeding (Fig. 1a, b). In addition, HF diet fed rats
had almost two fold less insulin sensitivity, as deter-
mined by homeostasis model assessment (HOMA) of
insulin resistance (Fig. 1c).
We also examined plasma concentrations of leptin,
which has postulated roles in obesity and insulin action
(Table 2). HF diet fed group presented significantly
higher leptin levels (19.1 ± 2.6 vs. 6.2 ± 1.2, P <0.05) than
St diet fed group.
Total cholesterol and triglycerides did not differ be-
tween groups (Table 2).
Gut microbiota, LPS and inflammatory status
To study whether HF diet could induce modifications
within the intestinal microbiota, we quantified some of
the main bacterial groups presented in fecal samples. Ana-
lysis of the bacterial 16S rDNA revealed that, at the
phylum level, animals from the HF diet group were char-
acterized for having lower Bacteroidetes and higher Firmi-
cutes to Bacteroidetes ratio (Table 3). Firmicutes/
Bacteroidetes ratio was positively correlated with weight
gain (r = 0.829, P <0.05) and AUC (r = −0.723, P <0.05)
while Bacteroidetes were negatively correlated with weight
gain (r = −0.800, P <0.05) and AUC (r = −0.716 P <0.05).
HF diet feeding also resulted in a decrease in the num-
ber of copies of Prevotella spp. and Lactobacillus spp.
(Table 3). We further determined whether fecal LPS levels
could be altered as a result of the changes in the gut
microbiota. Our data showed that fecal LPS levels seemed
to be more elevated in HF diet fed animals (Fig. 2a). In
addition, LPS levels were positively correlated with Firmi-
cutes/Bacteroidetes ratio (r = 0.787, P <0.05) and nega-
tively correlated with Bacteroidetes (r = −0.670, P <0.05).
Afterwards, we evaluated the colonic expression of toll-
like receptor 4 (TLR4) which is capable to recognize LPS.
In agreement with our LPS findings, TLR4 expression
tended to be increased in the colon of animals fed with
HF diet (Fig. 2b). Next, we investigated whether HF diet
and microbiota changes were associated with systemic
inflammation. In accordance, the chemokines MCP-1 and
Il-1β appeared to be more elevated in the plasma of HF
diet fed rats (Fig. 2c, d). LPS was positively correlated with
MCP-1 (r = 0.726, P <0.05).
I-FABP and GLP-2 in high fat-diet induced obesity
To understand the relationship between I-FABP, HF diet
feeding and systemic inflammation we quantified plasma
I-FABP levels and its intestinal expression in both
groups of rats. Surprisingly, plasma I-FABP levels were
decreased after HF diet feeding (Fig. 3a). On the other
Table 2 Energy ingestion, body composition and metabolic
parameters of Wistar rats fed either with standard (St) or
high-fat (HF) diet during 12 weeks
St HF P value
Energy ingested (Kcal/day) 57.9 ± 0.5 72.60 ± 0.1 <0.05
Weight gain (g) 134.7 ± 9.2 205.5 ± 15.4 <0.05
Fat mass (g) 166.8 ± 8.7 206.3 ± 8.6 <0.05
Total cholesterol (mg/dL) 64.3 ± 3.1 69.8 ± 6.6 0.78
Triglycerides (mg/dL) 79.3 ± 11.5 79.2 ± 8.3 0.83
Leptin (ng/mL) 6.2 ± 1.2 19.1 ± 2.6 <0.05
GLP-2 7.0 ± 0.4 9.8 ± 0.8 <0.05
Values are presented as mean ± SEM (n = 6 rats per group). GLP-2
glucagon-like peptide-2
Fig. 1 Glycaemic response during oral glucose tolerance test (a), total
area under the curve (AUC) (b) and homeostasis model assessment
(HOMA) (c) of Wistar rats after 7 weeks of feeding either with standard
(St) or high-fat (HF) diet. HOMA was calculated using the formula: fasting
glucose (mg/dL) × fasting insulin (ng/mL)/405. Data are presented as
mean ± SEM (n= 6 rats per group). * P< 0.05 vs respective St diet group
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hand, I-FABP relative expression in jejunum tended to
be higher in HF diet fed rats (Fig. 3b) which could be
considered an adaptive response to the increased dietary
fat content of the diet. To determine intestinotrophic
status of the animals we quantified GLP-2 plasma levels.
GLP-2 plasma levels were significantly increased after
HF diet feeding (Table 2). GLP-2 and intestinal expres-
sion of I-FABP seemed positively correlated with energy
ingested (r = 0.719, P <0.05 and r = 0.770, P = 0.07,
respectively).
To determine whether I-FABP plasma levels could be
used as a marker of the metabolic alterations and in-
flammatory status associated with obesity, we evaluated
the correlation between plasma I-FABP and host meta-
bolic and inflammatory parameters (Fig. 4). Plasma I-
FABP levels were negatively correlated with fecal LPS
(r = −0.806, P <0.05) and IL-1B (r = −0.623, P <0.05).
Discussion
Several studies have provided compelling evidence sug-
gesting an association between gut microbiome dysbio-
sis, obesity and low-grade inflammatory state [11].
In consonance with previous reports, we found that
the animals fed with HF diet had lower Bacteroidetes
and higher Firmicutes to Bacteroidetes ratio [10]. This
dysbiosis pattern might lead to an increased capacity
of harvesting energy from food [12, 13]. HF diet also
induced obesity and may have triggered intestinal
inflammation since fecal levels of LPS and TLR4
expression tended to be increased in the animals fed
with this diet. TLR4 is the LPS primary receptor that
mediates its proinflammatory effects [14]. As a result,
HF fed animals seemed to present higher plasma
levels of proinflammatory cytokines and developed
insulin resistance. As supported by other authors, it
appears to be a causative role for the gut bacteria-
induced proinflammatory state to the development of
weight gain and insulin resistance in rats under HF
diet [15, 16]. In this context, the gut barrier has an
important role in the prevention of LPS leakage from
the intestinal lumen to the portal blood. However, in
animal models of diet-induced obesity, intestinal bar-
rier function seems to be compromised [17].
In different intestinal diseases, I-FABP has emerged as
a potential biomarker of intestinal barrier dysfunction
Fig. 2 Fecal lipopolysaccharide (LPS) (a), intestinal expression of toll-like receptor 4 (TLR4) (b), plasma monocyte chemoattractant protein-1
(MCP-1) (c) and serum interleukin-1 beta (IL-1β) (d) of Wistar rats fed either with standard (St) or high-fat (HF) diet during 12 weeks. Data are
presented as mean ± SEM (n = 3–6 rats per group). * P < 0.05 vs respective St diet group
Table 3 Quantification of gut microbiota phyla, genera and
species in different experimental groups
St HF P value
Firmicutes/Bacteroidetes 1.03 ± 0.01 1.20 ± 0.03 <0.05
Firmicutes 6.61 ± 0.08 6.50 ± 0.09 0.35
Bacteroidetes 6.43 ± 0.10 5.45 ± 0.15 <0.05
Bacteroides spp. 4.36 ± 0.23 4.15 ± 0.50 0.18
Prevotella spp. 3.59 ± 0.29 2.21 ± 0.13 <0.05
Lactobacillus spp. 4.86 ± 0.27 3.77 ± 0.17 <0.05
Clostridium leptum 5.53 ± 0.04 5.43 ± 0.12 0.65
Bifidobacterium spp. 2.00 ± 0.24 2.12 ± 0.22 0.75
Values are presented as mean ± SEM and expressed as log10 16S rRNA gene copies/
20 ng of DNA (n= 6 rats per group). HF high-fat diet group, St standard diet group
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[18, 19]. Basal I-FABP plasma levels may reflect the
physiological turnover rate of enterocytes, whereas ele-
vated levels might indicate intestinal epithelial cell dam-
age [20]. Nevertheless, in the case of obesity-associated
metabolic diseases, the existent data about I-FABP and
intestinal barrier dysfunction is limited.
Verdam et al. have reported that chronically elevated
glucose levels in obese individuals were associated with
increased enterocyte loss, assumed by the increase on I-
FABP levels [21]. It was therefore speculated that the in-
creased enterocyte loss observed in subjects with
chronic hyperglycemia might had contributed to the im-
paired intestinal barrier function, thereby promoting
endotoxin-induced low-grade inflammation. However,
increased I-FABP levels could also be a result of an
increased production of I-FABP by enterocytes rather
than enterocyte loss.
Interestingly, in our study we found that the relative
expression of I-FABP tended to be increased in HF diet
fed rats. As intestinal absorption capacity can be adapted
to the dietary fat content, we hypothesize that HF diet
may had up-regulated several genes known to play an
important role in long-chain fatty acids uptake such as
I-FABP [22]. The animals fed with HF diet also showed
increased GLP-2 levels. GLP-2 is a 33 amino acid
peptide associated with intestinal growth and adaptation
in a variety of pathological conditions [23]. As suggested
by other authors, GLP2/GLP2R system may be increased
after HF diet to further promote fat absorption in the
intestine [23]. On the other hand, the inflammatory state
induced by microbiota changes after HF diet feeding
might have increased GLP-2 production in order to
improve the mucosal barrier integrity and, therefore,
blunt the inflammatory stress [2].
Conclusions
To our best knowledge, this is the first study demon-
strating that, inversely to what happens in other
Fig. 4 Correlations between plasma levels of intestinal fatty-acid binding protein (I-FABP) and host metabolic and inflammatory parameters. Data
of all experimental groups were gathered and analyzed using two-tailed Pearson’s correlation test
Fig. 3 Levels of plasma (a) and intestinal expression of intestinal fatty-acid binding protein (I-FABP) (b) of Wistar rats fed either with standard (St)
or high-fat (HF) diet during 12 weeks. Data are presented as mean ± SEM (n = 3–6 rats per group). * P < 0.05 vs respective St diet group
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intestinal inflammatory diseases, plasma I-FABP does
not positively correlates with the inflammatory status
presented in obesity. Instead, I-FABP is decreased in
plasma but probably increased in jejunum in order to
face dietary fat content. The search for noble biomarkers
has to continue since it is extremely important to antici-
pate the progression of obesity-associated metabolic dis-
eases and, thus, allowing the prevention or monitoring
of the therapeutic strategies use.
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